X0306 4 2021-04-16 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001633331 Lux Ventures IV, L.P. 920 BROADWAY, 11TH FLOOR NEW YORK NY 10010 0 0 1 0 0001722022 Lux Co-Invest Opportunities, L.P. 920 BROADWAY, 11TH FLOOR NEW YORK NY 10010 0 0 1 0 0001722021 Lux Co-Invest Partners, LLC 920 BROADWAY, 11TH FLOOR NEW YORK NY 10010 0 0 1 0 0001633332 Lux Venture Partners IV, LLC 920 BROADWAY, 11TH FLOOR NEW YORK NY 10010 0 0 1 0 Class A Common Stock 2021-04-16 4 P 0 100000 18.00 A 100000 I See footnote Common Stock 2021-04-20 4 C 0 17174594 A 17187095 I See footnote Common Stock 2021-04-20 4 C 0 17187095 D 0 I See footnote Class A Common Stock 2021-04-20 4 C 0 17187095 A 17287095 I See footnote Series A Preferred Stock 2021-04-20 4 C 0 10279275 0.00 D Common Stock 10279275 0 I See footnote Series B Preferred Stock 2021-04-20 4 C 0 3578653 0.00 D Common Stock 3578653 0 I See footnote Series C Preferred Stock 2021-04-20 4 C 0 1825883 0.00 D Common Stock 1825883 0 I See footnote Series D Preferred Stock 2021-04-20 4 C 0 1490783 0.00 D Common Stock 1490783 0 I See footnote 50,000 of these shares are held by Lux Co-Invest Opportunities, L.P. and 50,000 of these shares are held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. 3,018,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,156,084 of these shares are held by Lux Ventures IV, L.P. Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Represents shares held of record by Lux Ventures IV, L.P. Represents shares held of record by Lux Co-Invest Opportunities, L.P. Represents 298,156 shares held of record by Lux Ventures IV, L.P. and 1,192,627 shares held of record by Lux Co-Invest Opportunities, L.P. Lux Ventures IV LP, By:/s/ Peter Hebert, Managing Member 2021-04-20 Lux Co-invest Opportunities LP, By:/s/ Peter Hebert, Managing Member 2021-04-20 Lux Co-invest Partners LLC, By: /s/ Peter Hebert, Managing Member 2021-04-20 Lux Venture Partners IV, LLC, By: /s/ Peter Hebert, Managing Member 2021-04-20